Minerva Neurosciences, Inc.
NERVNasdaq
$4.27
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↑ +102.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$187.5M
Enterprise Value
$109.4M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$415.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
163.4%
ROIC
—
Debt / Equity
—
Net Cash
$78.1M
Return 1Y
+114.6%
Company profile
Minerva Neurosciences, Inc. focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for schizophrenia; MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for Parkinson's disease and other neurodegenerative disorders.
- CEO
- Rémy H. Luthringer
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9
- Headquarters
- Massachusetts
- Website
- minervaneurosciences.com
Earnings
NERV Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$2.86↑ +472.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.2M | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | $1.8M | -$45.4M | -$25.2M | -$23.1M | -$21.8M | -$15.1M |
| Net income | $1.9M | -$49.9M | -$32.1M | -$30.0M | $1.4M | -$293.4M |
| Diluted EPS | $0.05 | -$9.35 | -$6.01 | -$4.61 | $0.19 | -$34.67 |
| Operating cash flow | -$33.8M | -$24.6M | -$24.6M | -$14.8M | -$19.6M | -$13.5M |
| Free cash flow | — | — | -$24.7M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 4.5% | — | — | — | — | — |
| Net margin | 4.7% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$6.3M | -$4.4M | -$4.5M | -$3.9M | -$3.4M | -$2.8M | -$5.0M | -$16.7M |
| Net income | -$8.2M | $22.5M | -$4.3M | -$3.8M | -$3.3M | -$2.7M | -$283.7M | -$125.4M |
| Diluted EPS | -$1.09 | $2.97 | -$0.56 | -$0.50 | -$0.43 | -$0.36 | -$33.38 | -$2.86 |
| Operating cash flow | -$3.9M | -$4.4M | -$5.2M | -$4.1M | -$2.0M | -$2.9M | -$4.5M | -$5.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.